Inactive Instrument

Inter Pharma Share Price OTC Markets

IPTB.F

TH9474010005

Interpharma Public Company Limited is a Thailand-based company that develops, researches and distributes healthcare products and beauty initiatives for human beings, and healthcare products for animals. The Company provides wellness and anti-aging products, aesthetic innovation products, companion animal health products and livestock products. Its products include PREBO, YUUU toothpaste, multivitamin, Probac 7, Probac 10, Beta Glucan Plus, Pure Krill Oil, Astacurmin, YUUU cleansing mousse, Perfectha Complement, Perfectha Derm, Perfectha Deep, Perfectha Subskin and Uderma.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	263.93Cr 7.91Cr 6.94Cr 6.39Cr 5.99Cr 11Cr 746.3Cr 11Cr 77Cr 30Cr 368.84Cr 30Cr 29Cr 1.28TCr	P/E 2024	52.3x	P/E 2025	22.8x
Enterprise Value	275.86Cr 8.27Cr 7.25Cr 6.68Cr 6.26Cr 12Cr 780.03Cr 12Cr 80Cr 31Cr 385.51Cr 31Cr 30Cr 1.34TCr	EV / Sales 2024	1.13x	EV / Sales 2025	1.31x
Free-Float	-	Yield 2024 *	-	Yield 2025	1.59%

11/05	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02/03	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/03	Inter Pharma Public Company Limited announces Annual dividend, payable on May 25, 2026	CI
12/11	Inter Pharma Public Company Limited (SET:IP) agreed to acquire an additional 49% stake in Interpharma- ZEAvita Company Limited from Thai Union Ingredients.	CI
12/11	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/25/14	Inter Pharma Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
13/25/13	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
16/25/16	Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal	MT
16/25/16	Zhaoke Ophthalmology Limited Enters into Three Distribution and Supply Agreements with Interpharma Public Company Limited	CI
01/25/01	Inter Pharma Public Company Limited Signs Exclusive Distribution Agreement with Zhaoke Ophthalmology Company Limited for Comprehensive Eye Care Innovation	CI
25/25/25	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25/25/25	Inter Pharma Public Company Limited Proposes to Omit Dividend Payment for the Year Ended December 31, 2024	CI
14/24/14	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

17/22/17	Inter Pharma : New shares of IP to be traded on August 18, 2022	PU
10/22/10	Inter Pharma Public : Notification on Change of Directors and Authorization of Directors	PU
10/22/10	Inter Pharma Public : Report on the results of sale of common shares offered to private placement (F53-5)	PU
10/22/10	Inter Pharma Public : Right Adjustment of IP-W1 (Edited)	PU
10/22/10	Inter Pharma Public : Right Adjustment of IP-W1	PU

Manager	Title	Age	Since
Trinnawat Thanitnithiphan CEO	Chief Executive Officer	56	01/02/2014
Chatkaew Krudkosol DFI	Director of Finance/CFO	56	23/06/2023
Chompunuch Meevang CMP	Compliance Officer	54	-

Director	Title	Age	Since
Napaporn Dechakarat BRD	Director/Board Member	51	14/06/2017
Sansanee Chaiyaroj BRD	Director/Board Member	64	01/08/2020
Trinnawat Thanitnithiphan BRD	Director/Board Member	56	01/02/2014

Inter Pharma Share Price OTC Markets

Stocks

IPTB.F

TH9474010005

Pharmaceuticals

Valuation: Inter Pharma

Latest news : Inter Pharma

Press Releases: Inter Pharma

Managers and Directors: Inter Pharma

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTER PHARMA	-.--%	-.--%	-	-	7.91Cr
ELI LILLY AND COMPANY	+7.13%	+9.97%	+55.80%	+160.09%	1,07700Cr
JOHNSON & JOHNSON	+3.99%	+11.50%	+67.09%	+55.96%	61TCr
ABBVIE INC.	+4.20%	+17.03%	+38.97%	+91.06%	45TCr
ROCHE HOLDING AG	+0.99%	+4.85%	+28.17%	+23.89%	33TCr
ASTRAZENECA PLC	+1.82%	+8.19%	+40.04%	+27.95%	29TCr
NOVARTIS AG	+0.22%	+6.75%	+31.30%	+42.34%	29TCr
NOVO NORDISK A/S	+0.73%	+8.53%	-27.33%	-39.55%	21TCr
AMGEN INC.	+1.56%	+6.14%	+29.30%	+60.97%	19TCr
GILEAD SCIENCES, INC.	+3.26%	+3.33%	+15.55%	+68.24%	16TCr
Average	+2.39%	+8.00%	+30.99%	+54.55%	40.18TCr
Weighted average by Cap.	+3.85%	+8.93%	+41.75%	+80.17%

	2024	2025
Net sales	191.19Cr 5.73Cr 5.03Cr 4.63Cr 4.34Cr 8.13Cr 540.63Cr 8.3Cr 56Cr 22Cr 267.19Cr 22Cr 21Cr 926.5Cr	221.41Cr 6.64Cr 5.82Cr 5.36Cr 5.02Cr 9.42Cr 626.05Cr 9.61Cr 64Cr 25Cr 309.41Cr 25Cr 24Cr 1.07TCr
Net income	3.73Cr 11.17L 10L 9L 8L 15.85L 11Cr 16.18L 1.09Cr 42L 5.21Cr 41.96L 41.04L 18Cr	12Cr 36.68L 32.16L 29.65L 27.76L 52.05L 35Cr 53.13L 3.56Cr 1.38Cr 17Cr 1.38Cr 1.35Cr 59Cr
Net Debt	21Cr 62.62L 54.91L 50.61L 47.38L 88.85L 59Cr 90.7L 6.08Cr 2.35Cr 29Cr 2.35Cr 2.3Cr 101.24Cr	12Cr 35.76L 31.35L 28.9L 27.06L 50.73L 34Cr 51.79L 3.47Cr 1.34Cr 17Cr 1.34Cr 1.31Cr 58Cr